Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus induction chemotherapy and concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma
ChiCTR2300072956Phase 3Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Nov 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cadonilimab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2300072956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072956.